事关7000万患者，中国原研新药打破激素治疗恶性循环

Core Insights - The article discusses the challenges of managing atopic dermatitis (AD) in China, highlighting the issues of hormone abuse and the need for innovative treatments [1][2][3] - A new non-steroidal drug, Zeli Mei® (bimekizumab), has been approved for the treatment of AD, offering a potential solution to the ongoing cycle of flare-ups and treatment failures [2][3] Regulatory and Market Context - The current regulatory gray area and excessive marketing contribute to the widespread abuse of steroid medications for AD [2] - The prevalence of AD is increasing, with a reported incidence of 12.94% among children aged 1-7 years and 30.48% among infants aged 1-12 months in China [1] Treatment Challenges - Patients often resort to self-medication due to the availability of various topical treatments, leading to a dual challenge of overuse and fear of necessary steroid treatments [2] - Traditional steroid treatments are effective but can cause long-term skin damage, while non-steroidal options are safer but take longer to show results [2] Innovative Solutions - The introduction of Zeli Mei® represents a significant advancement, being the first aromatic hydrocarbon receptor (AhR) modulator approved for AD treatment in children over 2 years old and adults [3] - Clinical trials indicate that nearly 60% of patients experienced significant itch relief after 8 weeks of treatment, and 70% of patients remained relapse-free for 10 months after stopping the medication [3] Market Potential - China has approximately 70 million AD patients, with over 90% requiring topical treatments, indicating a substantial market opportunity for new therapies [3] - The market for eczema topical agents in China is projected to reach approximately 5.28 billion yuan in 2024, with steroid medications currently holding a significant market share [3]